Erratum: Can cetuximab affect paraneoplastic myopathy? (Journal Neurooncology 10.1007/s11060-009-9795-6);Can cetuximab affect paraneoplastic myopathy?

Journal of Neuro-Oncology

Volumn 93, Issue 3, 2009, Pages 437-438

  Galani, Eleni ^a   Bonakis, Anastasios ^b   Christodoulou, Christos ^a   Klouvas, George ^a   Angeliki, Drougou ^c   Skarlos, Dimostenis ^a  

^a METROPOLITAN HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c RED CROSS HOSPITAL   (Greece)

Author keywords

Cetuximab; Epidermal growth factor; Paraneoplastic myopathy

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; IMMUNOGLOBULIN; IRINOTECAN; METHYLPREDNISOLONE; OXALIPLATIN;

ADULT; ANAMNESIS; ARTICLE; BRONCHOSCOPY; CANCER GROWTH; CANDIDIASIS; CASE REPORT; COLON CANCER; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DRUG EFFICACY; GAIT DISORDER; HUMAN; KLEBSIELLA INFECTION; LIVER BIOPSY; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MUSCLE STRENGTH; MYOPATHY; PARANEOPLASTIC MYOPATHY; PERIPHERAL NEUROPATHY; WALKING;

EID: 67349098430     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9808-5     Document Type: Erratum

References (6)

1. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4):337-345. doi: 10.1056/NEJMoa033025
2. Levin MI, Mozaffar T, Al-Lozi MT, Pestronk A (1998) Paraneoplastic necrotizing myopathy: Clinical and pathological features. Neurology 50(3):764-767
3. Sampson JB, Smith SM, Smith AG, Singleton JR, Chin S, Pestronk A, Flanigan KM (2007) Paraneoplastic myopathy: Response to intravenous immunoglobulin. Neuromuscul Disord 17(5):404-408. doi: 10.1016/ j.nmd.2007.01.004
4. Iannello A, Ahmad A (2005) Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 24:487-499. doi: 10.1007/ s10555-005-6192-2
5. Kim J, Lee CK, Park HJ, Kim HJ, So HH, Lee KS, Lee HM, Roh HY, Choi WS, Park TK, Kim B (2006) Epidermal growth factor induces vasoconstriction through the phosphatidylinositol 3-kinase-mediated mitogen-activated protein kinase pathway in hypertensive rats. J Pharmacol Sci 101(2):135-143. doi: 10.1254/jphs.FP0060021
6. Florian JA, Watts SW (1999) Epidermal growth factor: A potent vasoconstrictor in experimental hypertension. Am J Physiol 276(3 Pt 2):H976-H983